Mylan Insulin Aspart (MYL1601D) Is Bioequivalent to Novolog (US-Licensed Insulin Aspart) and NovoRapid (EU-Approved Insulin Aspart)Yaron Raiter,Ulrike Hovelmann,Anoop Chullikana,Mark Liu,Charles M. Donnelly,Tracey Lawrence,Nilanjan Sengupta,Gopinath Ranganna,Abhijit Barve,C. L. GopuDIABETES(2021)引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要